Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell.
Cyrano Therapeutics has raised $9.0M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
Cyrano Therapeutics's investors include DeepWork Capital, Lumira Ventures, Remiges Ventures, DNV capital, Florida Opportunity Fund.
Cyrano Therapeutics is headquartered in Washington, United States.
Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell.
Cyrano Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cyrano Therapeutics — Funding & Investors." VCBacked, January 16, 2024, https://www.vcbacked.co/company/cyrano-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). Cyrano Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cyrano-therapeutics
{{cite web |title=Cyrano Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cyrano-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated